Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mardepodect Extension in Huntington's Disease
NCT02342548Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of mardepodect in Huntington's disease (HD) (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events at 1 year, Number of Participants With Laboratory Test Abnormalities at 1 year and 5 more. Started Feb 2015; status: terminated.
02
Drugs
mardepodect
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT02342548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342548.